JOP20170188A1 - ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting) - Google Patents
ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting)Info
- Publication number
- JOP20170188A1 JOP20170188A1 JOP/2017/0188A JOP20170188A JOP20170188A1 JO P20170188 A1 JOP20170188 A1 JO P20170188A1 JO P20170188 A JOP20170188 A JO P20170188A JO P20170188 A1 JOP20170188 A1 JO P20170188A1
- Authority
- JO
- Jordan
- Prior art keywords
- sting agonists
- cyclic dinucleotides
- sting
- compounds
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
كشف هذا الاختراع عن مركبات وتركيبات وطرق لعلاج العدوى الفيروسية أو الأمراض أو المتلازمات أو الاضطرابات التي تتأثر بتعديل STING. وتلك المركبات يتم تمثيلها بالصيغة (I) كما يلي: الصيغة (I) حيث تم تعريف R1A وR1B وR1c وB1 وR2A وR2B بهذه الوثيقة.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662426350P | 2016-11-25 | 2016-11-25 | |
US201762502983P | 2017-05-08 | 2017-05-08 | |
US201762555232P | 2017-09-07 | 2017-09-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
JOP20170188A1 true JOP20170188A1 (ar) | 2019-01-30 |
Family
ID=60937846
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2017/0188A JOP20170188A1 (ar) | 2016-11-25 | 2016-11-25 | ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting) |
Country Status (13)
Country | Link |
---|---|
US (2) | US11472830B2 (ar) |
EP (1) | EP3544989A1 (ar) |
JP (2) | JP7316936B2 (ar) |
KR (1) | KR20190085107A (ar) |
CN (1) | CN110291096A (ar) |
AU (1) | AU2017365158B2 (ar) |
BR (1) | BR112019010606A2 (ar) |
CA (1) | CA3044693A1 (ar) |
JO (1) | JOP20170188A1 (ar) |
MX (1) | MX2019006082A (ar) |
TW (1) | TW201831192A (ar) |
UY (1) | UY37495A (ar) |
WO (1) | WO2018098203A1 (ar) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HRP20221263T1 (hr) | 2016-03-18 | 2023-03-03 | Immune Sensor, Llc | Ciklički di-nukleotidni spojevi i postupci uporabe |
US11098077B2 (en) | 2016-07-05 | 2021-08-24 | Chinook Therapeutics, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
CA3040143A1 (en) | 2016-10-14 | 2018-04-19 | Precision Biosciences, Inc. | Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome |
JOP20170192A1 (ar) | 2016-12-01 | 2019-01-30 | Takeda Pharmaceuticals Co | داي نوكليوتيد حلقي |
WO2018138685A2 (en) * | 2017-01-27 | 2018-08-02 | Janssen Biotech, Inc. | Cyclic dinucleotides as sting agonists |
CN110234404A (zh) * | 2017-01-27 | 2019-09-13 | 詹森生物科技公司 | 作为sting激动剂的环状二核苷酸 |
US20200055883A1 (en) | 2017-02-17 | 2020-02-20 | Eisai R&D Management Co., Ltd. | Cyclic di-nucleotides derivative for the treatment of cancer |
TWI808092B (zh) | 2017-08-30 | 2023-07-11 | 中國大陸商北京軒義醫藥科技有限公司 | 作為干擾素基因調節劑之刺激劑的環狀二核苷酸 |
WO2019084060A1 (en) | 2017-10-24 | 2019-05-02 | Silverback Therapeutics, Inc. | CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS |
PE20210156A1 (es) | 2017-11-10 | 2021-01-26 | Takeda Pharmaceuticals Co | Compuestos moduladores de sting y metodos de elaboracion y uso |
CN111566120B (zh) | 2017-12-20 | 2023-09-29 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的3’3’环状二核苷酸 |
WO2019123339A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
PL3759109T3 (pl) | 2018-02-26 | 2024-03-04 | Gilead Sciences, Inc. | Podstawione związki pirolizyny jako inhibitory replikacji hbv |
EP3774883A1 (en) | 2018-04-05 | 2021-02-17 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | 2,2,─環二核苷酸 |
JP7296398B2 (ja) | 2018-04-06 | 2023-06-22 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール,ヴイ.ヴイ.アイ. | 3’3’-環状ジヌクレオチド |
TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
TW202014193A (zh) | 2018-05-03 | 2020-04-16 | 捷克科學院有機化學與生物化學研究所 | 包含碳環核苷酸之2’3’-環二核苷酸 |
US20210205348A1 (en) | 2018-06-01 | 2021-07-08 | Eisai R&D Management Co., Ltd. | Methods for the Treatment of Bladder Cancer |
TW202030199A (zh) * | 2018-07-17 | 2020-08-16 | 美商健生生物科技公司 | 作為sting促效劑之環狀二核苷酸 |
WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
CA3099904A1 (en) | 2018-08-16 | 2020-02-20 | Eisai R&D Management Co., Ltd. | Salts of compounds and crystals thereof |
CA3111784A1 (en) | 2018-09-12 | 2020-03-19 | Silverback Therapeutics, Inc. | Methods and compositions for the treatment of disease with immune stimulatory conjugates |
JP7218431B2 (ja) | 2018-09-21 | 2023-02-06 | シャンハイ ドーァ ノボ ファーマテック カンパニー,リミティド | 環状ジヌクレオチド類似体、その医薬組成物及び使用 |
US11110106B2 (en) | 2018-10-29 | 2021-09-07 | Venenum Biodesign, LLC | Sting agonists for treating bladder cancer and solid tumors |
US11161864B2 (en) | 2018-10-29 | 2021-11-02 | Venenum Biodesign, LLC | Sting agonists |
WO2020092528A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
MX2021005047A (es) | 2018-10-31 | 2021-09-08 | Gilead Sciences Inc | Compuestos de 6-azabenzimidazol sustituidos como inhibidores de hpk1. |
CN111655712B (zh) * | 2018-12-29 | 2021-02-05 | 上海济煜医药科技有限公司 | 作为肿瘤免疫类的化合物及其应用 |
DK3934757T3 (da) | 2019-03-07 | 2023-04-17 | Inst Of Organic Chemistry And Biochemistry Ascr V V I | 2'3'-cykliske dinukleotider og prodrugs deraf |
US20220143061A1 (en) | 2019-03-07 | 2022-05-12 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
EP3935065A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
CN109929894B (zh) * | 2019-04-17 | 2021-06-01 | 中国农业科学院兰州兽医研究所 | 一种猪源第二信使分子2′3′-cGAMP的制备及活性鉴定方法 |
TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
EP3962493A2 (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor |
JP2022531899A (ja) | 2019-05-09 | 2022-07-12 | アリゴス セラピューティクス インコーポレイテッド | Stingモジュレータとしての修飾環状ジヌクレオシド化合物 |
KR20220006519A (ko) | 2019-05-10 | 2022-01-17 | 다케다 야쿠힌 고교 가부시키가이샤 | 항체 약물 접합체 |
TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
BR112021026376A2 (pt) | 2019-06-25 | 2022-05-10 | Gilead Sciences Inc | Proteínas de fusão flt3l-fc e métodos de uso |
EP3993834A1 (en) | 2019-07-05 | 2022-05-11 | Tambo, Inc. | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
PE20221111A1 (es) | 2019-09-30 | 2022-07-11 | Gilead Sciences Inc | Vacunas para vhb y metodos de tratamiento de vhb |
CA3151322A1 (en) | 2019-10-01 | 2021-04-08 | Silverback Therapeutics, Inc. | Combination therapy with immune stimulatory conjugates |
WO2021113765A1 (en) | 2019-12-06 | 2021-06-10 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
US11179473B2 (en) | 2020-02-21 | 2021-11-23 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
CN115605493A (zh) | 2020-03-20 | 2023-01-13 | 吉利德科学公司(Us) | 4′-c-取代的-2-卤代-2′-脱氧腺苷核苷的前药及其制备和使用方法 |
KR20220167275A (ko) | 2020-04-10 | 2022-12-20 | 오노 야꾸힝 고교 가부시키가이샤 | 암 치료 방법 |
EP4149440A1 (en) | 2020-05-11 | 2023-03-22 | Erytech Pharma | Red cell extracellular vesicles (rcevs) containing cargoes and methods of use and production thereof |
JP2023532304A (ja) | 2020-07-01 | 2023-07-27 | エーアールエス ファーマシューティカルズ オペレーションズ,インク. | 抗asgr1抗体コンジュゲートおよびその使用 |
WO2022031894A1 (en) | 2020-08-07 | 2022-02-10 | Gilead Sciences, Inc. | Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use |
WO2022032191A1 (en) | 2020-08-07 | 2022-02-10 | Tambo, Inc. | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
AU2021363267A1 (en) * | 2020-10-20 | 2023-06-22 | Tyligand Bioscience (Shanghai) Limited | Multifunctional cyclic dinucleotide and use thereof |
PE20231947A1 (es) | 2020-11-09 | 2023-12-05 | Takeda Pharmaceuticals Co | Conjugados de anticuerpo y farmaco |
KR20240006683A (ko) | 2021-05-13 | 2024-01-15 | 길리애드 사이언시즈, 인코포레이티드 | TLR8 조절 화합물과 항-HBV siRNA 치료제의 조합물 |
US20220389394A1 (en) | 2021-05-18 | 2022-12-08 | Gilead Sciences, Inc. | METHODS OF USING FLT3L-Fc FUSION PROTEINS |
US20230046340A1 (en) | 2021-06-23 | 2023-02-16 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
CA3222595A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
CA3220923A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1645561A1 (en) * | 2003-07-15 | 2006-04-12 | Mitsui Chemicals, Inc. | Method of synthesizing cyclic bisdinucleoside |
PL2934598T3 (pl) * | 2012-12-19 | 2018-10-31 | Board Of Regents, The University Of Texas System | Środek farmaceutyczny ukierunkowany na ssaczy szlak przekazywania sygnału przez cykliczne dinukleotydy |
PE20160167A1 (es) | 2013-04-29 | 2016-04-21 | Sloan Kettering Inst Cancer | Composiciones y metodos para alterar la senalizacion del segundo mensajero |
US9549944B2 (en) * | 2013-05-18 | 2017-01-24 | Aduro Biotech, Inc. | Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling |
US9724408B2 (en) * | 2013-05-18 | 2017-08-08 | Aduro Biotech, Inc. | Compositions and methods for activating stimulator of interferon gene-dependent signalling |
JP2016535731A (ja) * | 2013-10-21 | 2016-11-17 | ドレクセル ユニバーシティ | 慢性b型肝炎ウイルス感染を処置するためのstingアゴニストの使用 |
EP3546473A1 (en) * | 2014-12-16 | 2019-10-02 | Kayla Therapeutics | Cyclic [(2',5')p(3',5')p]-dinucleotides for cytokine induction |
US20180344758A1 (en) | 2014-12-17 | 2018-12-06 | Lipogen Llc | Method of Treating Cancer with cGAMP or cGAsMP |
GB201501462D0 (en) * | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
KR102271750B1 (ko) | 2015-08-13 | 2021-06-30 | 머크 샤프 앤드 돔 코포레이션 | Sting 효능제로서 시클릭 디-뉴클레오티드 화합물 |
WO2017075477A1 (en) * | 2015-10-28 | 2017-05-04 | Aduro Biotech, Inc. | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling |
MX363780B (es) * | 2015-12-03 | 2019-04-03 | Glaxosmithkline Ip Dev Ltd | Dinucleótidos de purina cíclica como moduladores del estimulador de los genes de interferón. |
HRP20221263T1 (hr) * | 2016-03-18 | 2023-03-03 | Immune Sensor, Llc | Ciklički di-nukleotidni spojevi i postupci uporabe |
-
2016
- 2016-11-25 JO JOP/2017/0188A patent/JOP20170188A1/ar unknown
-
2017
- 2017-11-21 EP EP17825988.3A patent/EP3544989A1/en active Pending
- 2017-11-21 MX MX2019006082A patent/MX2019006082A/es unknown
- 2017-11-21 AU AU2017365158A patent/AU2017365158B2/en active Active
- 2017-11-21 CA CA3044693A patent/CA3044693A1/en active Pending
- 2017-11-21 JP JP2019528031A patent/JP7316936B2/ja active Active
- 2017-11-21 KR KR1020197018101A patent/KR20190085107A/ko active IP Right Grant
- 2017-11-21 BR BR112019010606A patent/BR112019010606A2/pt unknown
- 2017-11-21 WO PCT/US2017/062901 patent/WO2018098203A1/en unknown
- 2017-11-21 CN CN201780084645.XA patent/CN110291096A/zh active Pending
- 2017-11-22 US US15/820,592 patent/US11472830B2/en active Active
- 2017-11-23 TW TW106140679A patent/TW201831192A/zh unknown
- 2017-11-24 UY UY0001037495A patent/UY37495A/es unknown
-
2022
- 2022-05-20 JP JP2022082784A patent/JP2022110131A/ja active Pending
- 2022-10-17 US US17/967,443 patent/US20230144627A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2017365158A1 (en) | 2019-06-06 |
KR20190085107A (ko) | 2019-07-17 |
MX2019006082A (es) | 2019-11-12 |
UY37495A (es) | 2018-05-31 |
BR112019010606A2 (pt) | 2019-09-17 |
WO2018098203A1 (en) | 2018-05-31 |
AU2017365158B2 (en) | 2022-02-17 |
US20180162899A1 (en) | 2018-06-14 |
JP2020500862A (ja) | 2020-01-16 |
CA3044693A1 (en) | 2018-05-31 |
TW201831192A (zh) | 2018-09-01 |
EP3544989A1 (en) | 2019-10-02 |
JP2022110131A (ja) | 2022-07-28 |
CN110291096A (zh) | 2019-09-27 |
US11472830B2 (en) | 2022-10-18 |
US20230144627A1 (en) | 2023-05-11 |
JP7316936B2 (ja) | 2023-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JOP20170188A1 (ar) | ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting) | |
WO2018138685A3 (en) | Cyclic dinucleotides as sting agonists | |
MX2019007540A (es) | Derivados de pirazol como inhibidores de malt1. | |
EA201891910A1 (ru) | Гетероарильные ингибиторы pad4 | |
MX2020006290A (es) | Dinucleotidos ciclicos como agonistas de sting. | |
PH12016501254A1 (en) | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection | |
PH12016501192B1 (en) | Tetrahydropyridopyrazines modulators of gpr6 | |
EA030115B9 (ru) | Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b | |
GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
MX2020001757A (es) | Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades. | |
PH12019501359A1 (en) | Polymorphs | |
MX2015010937A (es) | Composiciones para la movilizacion, autodireccion, expansion y diferenciacion de celulas madre y metodos para usar las mismas. | |
EA201890256A1 (ru) | 2-амино-3-фтор-3-(фторметил)-6-метил-6-фенил-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1 | |
PH12017500653A1 (en) | Substituted benzothiophenyl derivatives as gpr40 agonists for the treatment of type ii diabetes | |
PH12016502003A1 (en) | Novel bacteriophage and composition containing same | |
MX2019005934A (es) | Compuestos de benzodiazolio como inhibidores del canal de sodio epitelial (enac). | |
MX2018009325A (es) | Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn). | |
EA201891347A1 (ru) | Аза-бензимидазольные ингибиторы pad4 | |
TW201613878A (en) | Pyrazine GPR40 agonists for the treatment of type II diabetes | |
PH12016501999A1 (en) | Novel bacteriophage and composition containing same | |
EA201692358A1 (ru) | Производные изоиндолина для применения в лечении вирусной инфекции | |
MX2016001855A (es) | Nuevos aza-oxo-indoles para el tratamiento y profilaxis de la infeccion por virus sincitial respiratorio. | |
PH12016502001A1 (en) | Novel bacteriophage and composition comprising same | |
EA201791530A1 (ru) | НОВЫЕ N-АЦИЛАРИЛСУЛЬФОНАМИДНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ АМИНОАЦИЛ-тРНК СИНТЕТАЗЫ | |
PH12020552172A1 (en) | Cyclic dinucleotides as sting agonists |